ThromboGenics NV has announced that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA® is listed in the ...

Please provide your email address to receive an email when new articles are posted on . ThromboGenics announced positive topline results from the OASIS study of Jetrea in patients with symptomatic ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ocriplasmin (Jetrea, Thrombogenics, NV) for the treatment of adults with ...

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced that the UK’s National Institute for Health and Care Excellence (NICE ...

BRUSSELS (Reuters) – Belgian biotechnology company ThromboGenics said late on Monday that sales in the United States of its only drug, eye disease treatment Jetrea, had slowed in the second half of ...

Please provide your email address to receive an email when new articles are posted on . ThromboGenics has started to evaluate Jetrea as a potential treatment for retinal vein occlusion, according to a ...

ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for ...

The European Commission has approved the intravitreal eye injection Jetrea, produced by Novartis eye care subsidiary Alcon, for treating vitreomacular traction in the European Union. The disease, ...

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has ...